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Overexpression of themiR-17-92 cluster is a key oncogenic event in various cancer types.
The oncogenic effect of the miR-17-92 cluster is enhanced by cooperation between its
members in targeting tumor-suppressive proteins and pathways such as PTEN and TGFβ
signaling. However, in the case of miR-19a and miR-19b, these have been shown to
have a preponderant role in the cluster’s oncogenicity. Important studies have revealed
the influence of the Myc proto-oncogene family in the transcriptional regulation of miR-
17-92. Recent findings show that other oncogenic signaling pathways, such as those
of Notch and Sonic Hedgehog, activate miR-17-92 in cancer. Notwithstanding, another
layer of complexity has been added by the influence of the relevant primary miR-17-
92 tertiary structure during processing to mature miRNA. In this review, we attempt to
integrate current transcriptional and post-transcriptional knowledge to enhance our global
understanding of the coordinated up-regulation of miR-17-92 in cancer.
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Introduction
MicroRNAs (miRNAs), a class of small non-coding RNAs (~22 nucleotides), negatively regulate
protein translation of target mRNAs post-transcriptionally to fine-tune the control of cell homeosta-
sis. However, the unbalanced expression ofmiRNA is a hallmark of several diseases, including cancer
(1). In this regard, “oncomiR” refers to a miRNA that induces or potentiates oncogenic signaling
when its expression is deregulated in cancer. Some oncomiRs, per se, have a substantial influence on
oncogenic processes, such as miR-17-92 (oncomiR-1).
A plethora of important studies corroborate a major oncogenic role for the miR-17-92 cluster
as a driver or secondary event that enhances the oncogenic process in different cancer types (2).
Therefore, in this mini review, we intend to focus on several novel findings concerning the biological
role of miR-17-92 and newmolecular aspects of miR-17-92 transcriptional and post-transcriptional
regulation.
Biological Role of the miR-17-92 Cluster
The miR-17-92 cluster (oncomiR-1) is located in an intron of MIR17HG [miR-17-92 cluster host
gene (non-protein coding)] on chromosome 13 (13q31.3) (3). The primary transcript of miR-
17-92 (pri-miR-17-92) is a ~0.8-kb-long polycistron that is processed into seven different mature
miRNAs: miR-17 (miR-17-5p andmiR-17-3p), miR-18a, miR-19a, miR-19b, miR-20a, andmiR-92a.
This genomic locus, previously described as C13orf25, is amplified in hematopoietic malignancies
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(13q31–q32 amplification) (4), with overexpression of miR-17-92
observed in several types of cancer, including lung, breast, colon,
pancreas, prostate, thyroid, and lymphoma (3, 5–8).
The artificial manipulation of miR-17-92 expression in trans-
genic mice showed that the cluster is essential to normal mouse
development (9, 10), with the correct timing of miR-17-92 acti-
vation essential to lung development (9). A high abundance of
miR-17-5p, miR-18, miR-19b, miR-20a, andmiR-92 was observed
at the E11.5 stage of mouse development, while at E17.5, miR-
17-92 levels were reduced. In studies of transgenic mice where
miR-17-92 overexpression was targeted to lung epithelium using
the surfactant protein C promoter, the authors observed abnormal
lung development, consisting of very few normal alveoli and with
obvious epithelia hyperplasia, and mice dying soon after birth
(9). Indeed, high levels of miR-17-92 expression are observed in
aggressive lung cancer (5), pointing to a role for the cluster in lung
cancer oncogenesis.
The generation of knock-outs of miR-17-92 (miR-17-
92∆neo/∆neo) in newborn mice resulted in death soon after birth
(10). The cause of the observed post-natal lethality was severe
hypoplastic lungs and ventricular septal defects. In humans,
the homozygous germline deletion of MIR17HG significantly
reduced mature miR-17-92 levels and is associated with a
syndrome characterized by microcephaly, short stature, and
digital defects (11). These developmental abnormalities were
recapitulated in transgenic mice with a targeted deletion of
miR-17-92.
Oncogenic Role of the miR-17-92 Cluster
The integration of different datasets from The Cancer Genome
Atlas, available from the online cBioportal for Cancer Genomics
website, does not show major genetic alterations in MIR17HG
in different types of cancer, despite a few cases of genomic
amplification (below 10% in some cancers) (12). This indicates
that transcriptional (Figure 1) and post-transcriptional processes
of miR-17-92 are the key in regulating mature miRNA levels.
An initial report that miR-17-92 contributed to B-cell lym-
phomagenesis in Eu-myc transgenicmice pointed to an oncogenic
role for the cluster (3). In this model, lymphoma is driven by c-
Myc oncogene overexpression controlled by an immunoglobulin
heavy-chain enhancer (Eu-myc) in transgenic mice, and overex-
pression of the miR-17-92 cluster accelerates the development of
c-Myc-induced B-cell lymphoma.
Two independent studies have shown a causative oncogenic
role for miR-17-92 in lymphomagenesis as a bona fide oncogene
(13, 14). In the first, the targeted expression of miR-17-92 to
B cells (Eµ-miR-17-92 mice) led to the development of B-cell
malignancy (three classes of B-cell lymphoma or leukemia) with
high penetrance (~80%) and massive spleen enlargement (14). In
the second study, targeted miR-17-92 expression to B cells (miR-
17-92 Tg/Tg; CD19 Cre) also induced B-cell lymphoma develop-
ment, followed by PTEN down-regulation and enhancement of
the mTOR pathway (13), altogether, showing a potent oncogenic
role for miR-17-92 per se.
Several lines of evidence reveal the importance of balancing
the expression of mature miRNAs to elicit oncogenic effects.
Two independent studies dissected the contribution of singular
miR-17-92 components to reveal that miR-19a and miR-19b are
the key oncogenic miRNAs in the cluster (15, 16). Firstly, Olive
et al. showed enhanced lethality of irradiated mice when injected
with Eµ-myc hematopoietic stem and progenitor cells selectively
transduced with miR-19b (16). Moreover, a specific mutation to
disrupt the hairpin stem of miR-19a and miR-19b, and conse-
quently the biogenesis of these mature miRNAs, caused a delay
in the onset of B-cell lymphoma and reduced animal deaths.
Importantly, in the second study, Mu et al. showed that deletion
of the entire miR-17-92 reduced B-cell lymphoma proliferation in
FIGURE 1 | Coordinated transcriptional activation of miR-17-92 by oncogenic signaling pathways synergistically down-regulates important negative
regulators of cell growth and proliferation signaling in cancer.
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Eu-myc transgenic mice (15). Moreover, selective overexpression
of miR-19a and miR-19b in Eu-myc transgenic mice rescued the
growth advantage of lymphoma cells.
More recently, Han et al. showed the essential role of miR-19
in prostate cancer tumorigenesis in mice presenting high levels
of c-Myc (Hi-Myc; miR-17-92+/+) targeted to prostate cells. In
these animals, at the age of 10months, invasive prostate cancer is
detected in all animals, whereas no invasive tumor is observed in
the miR-19 deleted mice (Hi-Myc; miR-17-92∆19/∆19) (17).
Disruption of the miR-19:miR-92 ratio to enhancemiR-19 over
miR-92 levels is observed in pre-malignant and malignant Eu-
myc B cells compared with normal B cells (18). Moreover, the
molecular manipulation of miR-92 levels to overcome miR-19 in
Eu-myc B cells induced apoptosis by caspase activation. In thyroid
cancer, induction of the BRAF oncogene leads to overexpression
of miR-17-92 cluster components, with a clear shift of miR-19a/b
levels to overcome miR-92a. Interestingly, the protective effect
of high iodine treatment was observed by blocking an miR-19
increase while miR-92 levels remained the same (19). These stud-
ies reinforce evidence formiR-19 as the oncogenicmiRNA and for
miR-92 as a negative regulator of the cluster.
Transcriptional Regulation and Processing
of miR-17-92
Two major mechanisms are involved in the regulation of mature
miR-17-92 levels: transcriptional, which implicate promoter acti-
vation/repression, and post-transcriptional, which concern pre-
dominantly primary miRNA processing. In this regard, not only
does the classical importance of oncogenic pathways emerge but
also the role of pri-miRNA tertiary structure processing and the
action of RNA-binding proteins.
To understand the transcriptional regulation of miR-17-92, it
is imperative to analyze its putative promoter region. One of the
best characterized regulators of miR-17-92 transcription is the
proto-oncogene, c-Myc, which is amplified in different types of
tumors (12). The miR-17-92 putative promoter region in both
humans and rodents presents consensus-binding sites for c-Myc.
The overexpression of c-Myc induces its binding to the miR-17-
92 promoter and activates cluster transcription in HeLa cells (20),
whereas the knock-down of c-Myc drastically reduces miR-17-92
levels in the same cell line (21).
The expression of miR-17-92 is also induced by another mem-
ber of theMyc family, N-myc, a target of the activation of the Sonic
Hedgehog (SHH)/Patched signaling pathway in medulloblastoma
(22). Overexpression of N-myc, or the treatment of cerebellar
granule neuron precursors with exogenous Shh, induces miR-17-
92 in vitro, and also medulloblastoma derived from Patched+/ 
or SmoA1 mice shows overexpression of miR-17-92 (22). Among
miRNAclustermembers,miR-19 is the highest expressed in SHH-
derived medulloblastoma (Patched+/ ) and the treatment with
anti-miR-19 intravenously inhibited xenograft tumor growth (23).
Indeed, miR-17-92 is required for medulloblastoma formation
as the cluster deletion in a transgenic Patched+/  mouse model
blocked tumor development (24). Altogether, these studies indi-
cate an important role for the Myc family in the transcription of
the miR-17-92 cluster.
Regardless of the classical influence of c-Myc upon miR-
17-92 transcription, Notch signaling plays an important role
in the regulation of miR-17-92 levels. The putative miR-17-92
promoter presents predicted binding sites for HES1, a Notch
signaling effector. Notch signaling is overexpressed in thyroid
cancer (25) and NOTCH1 knock-down reduces miR-19 lev-
els in papillary thyroid cancer (19). The activation of Notch
intracellular domain (NICD) induces substantial miR-17-92
expression in normal thyroid follicular cells, while BRAFV600E
oncogene induction also increases miR-17-92 via Notch signaling
activation.
Cooperation between miR-19 and Notch1 activation was also
observed in T-cell acute lymphoblastic leukemia (T-ALL) (26).
In this study, NOTCH1 gene translocation t(9;14)(q34;q11) was
found concomitant with the miR-17-92 cluster t(13;14)(q32;q11)
in one leukemic clone. Moreover, the transduction of hematopoi-
etic progenitor cells to overexpress the NICD, and posterior
implantation into irradiated receptor mice, caused T-ALL in 20%
of animals, while the concomitant transduction of NICD together
with miR-19 lead to 100% of animals developing T-ALL after
2months. The high frequency of Notch1-activating mutations in
T-ALL, occurring in more than 50% of clinical cases (27), and the
higher expression of miR-19 in these patients (28) highlight the
important cooperation between Notch signaling and miR-17-92
in T-ALL.
Although transcribed as a single primary transcript, pri-
miR-17-92 processing produces distinct singular mature miRNA
levels, indicating the existence of a differential processing
mechanism. Recent studies elegantly showed that the molecu-
lar structure of pri-miR-17-92 at secondary and tertiary lev-
els conferred intrinsic characteristics that influenced miRNA
processing.
Pri-miR-17-92 is transcribed as a long ~800 nt RNA that folds
into a characteristic globular tertiary structure, which enables dif-
ferential processing to yield mature miRNAs (29). The molecular
structure of the folded RNA presents regions that are solvent
accessible or inaccessible, culminating in differential enzymatic
access and processing. Indeed, the Drosha enzyme’s access to the
30-core domain of miRNAs (miR-19b and miR-92a) is impaired
due to such globular folding. Moreover, deletion of the 50-region
of the cluster abrogates this protection, as does deletion of the
miR-19 precursor itself or an non-miRNA containing stem-loop
(NMSL) sequence, resulting in the processing of miR-92a (29).
The NMSL region is located between miR-19b and miR-92a, and
forms tertiary contacts with pre-miR-19b that represses Drosha
processing of pre-miR-92a, and contributes to the maintenance
of pri-miR-17-92 globular structure (30). Moreover, biochemical
properties of pri-miR-17-92’s three-dimensional structure confer
a kinetic barrier to its processing and influences protein recogni-
tion sites (31).
Nevertheless, these studies do not consider the possible exis-
tence of an interaction between RNA-binding proteins and
the pri-miR-17-92 cluster to modulate its processing. Indeed,
hnRNP A1 interacts with miR-17-92 and facilitates the pro-
cessing of pre-miR-18 (32). Therefore, the existence of an as
yet to be characterized mechanism, whereby RNA-binding pro-
teins selectively enhance or blunt miR-17-92 components, could
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TABLE 1 | Validated miR-17-92 targets.
Validated targets miR-17-92 cluster Reference
miR-17 miR-18a miR-19a miR-19b miR-20a miR-92a
PTEN x x x x x (6, 15, 16)
SMAD4 x x x (19, 33, 34)
TGFBR2 x x (33, 34)
CDKN1A (P21) x x (35)
contribute to miR-17-92’s fine-tuned expression and tissue
specificity.
Targeting of Tumor-Suppressive Pathways
in Cancer by miR-17-92
The target prediction of miR-17-92 components, based on seed
sequence homology, divides the miRNAs into four families: miR-
17 (miR-17 and 20), miR-18, miR-19 (miR-19a and 19b), and
miR-92 families. A single, predicted target mRNA is frequently
observed to harbor multiple binding sites for miR-17-92 com-
ponents in the 30-UTR, indicating a synergistic mechanism of
action.
An important target of the miR-17-92 cluster is the tumor
suppressor PTEN (Table 1) (6, 15, 16). The existence of multiple
conserved binding sites for miR-19a/b, miR-17, and miR-20a in
the 30-UTR of PTEN mRNA highlights the cooperative effect
of miR-17-92 cluster components in blunting key mRNAs to
enhance oncogenesis. The down-regulation of PTEN levels is a
key step during tumorigenesis and potentiates the activation of
AKT/mTOR growth and survival signaling. Indeed, overexpres-
sion of miR-19 causes a strong inhibition of PTEN levels and the
enhancement of pAkt. Also, an important increase in the phos-
phorylation of the S6 ribosomal protein is observed, indicative of
the activation ofmTOR signaling (16). In vivo, the deletion ofmiR-
17-92 in Eu-myc B-cells results in a lymphoma showing increased
levels of PTEN in nude mice (15).
Another important tumor-suppressive pathway targeted by sev-
eral members of miR-17-92 is the TGFβ signaling pathway (36),
reinforcing the synergistic role of cluster miRNAs (Table 1). The
TGFβ signaling pathway is an important regulator of epithelial
cell proliferation, triggering an antiproliferative signal mediated
by p21. However, miR-17-92-mediated blunting of signal trans-
duction by TGFβ, by down-regulating its signaling components,
would enhance cell proliferation and make cancer cells refractory
to TGFβ1 signaling.
Recent studies have confirmed that TGFBR2 is targeted by
miR-17/20, while SMAD2/SMAD4 is regulated by miR-18 in
neuroblastoma cells (33). Moreover, Smad4 is also a target of
miR-19a/miR-19b in thyroid follicular cells (19). Indeed, in thy-
roid cancer, BRAF-mediated miR-17-92 up-regulation leads to a
reduction of Smad4 and Tgfbr2 proteins and a loss of responsive-
ness to TGFβ1. The blockage of miR-19a/b with anti-miR restores
TGFβ1 G1 cell cycle arrest in thyroid cancer cells. In glioblastoma
cells, activation ofmiR-17-92 bluntedTGFβ-induced gene expres-
sion signature (34). In addition, miR-20 targets CDKN1A (P21),
an important negative regulator of cell cycle progression activated
by TGFβ in colorectal cancer cells and blocks TGFβ-induced
antiproliferative effect (35).
Future Directions
To functionally understand the biogenesis of mature miR-17-92
miRNAs, it is necessary to integrate transcriptional and post-
transcriptional regulatory mechanisms.
Myc family genes exert important transcriptional effects on
miR-17-92; however, a considerable fraction of cancers do not
show genetic alterations in these proto-oncogenes. In this regard,
the activation of oncogenic signaling, such as Shh and Notch, is
involved in the transcriptional activation of miR-17-92. Never-
theless, many other predicted oncogenic transcription factorsmay
bind to, and regulate, the miR-17-92 promoter.
Furthermore, after primary miR-17-92 transcription, its post-
transcriptional regulation is responsible for fine-tuning the gener-
ation of miR-17-92 miRNAs. The molecular tertiary structure of
themiR-17-92 primary transcript emerges as an importantmodu-
lator of miRNA processing machinery, but does not fully explain
the distinct patterns in expression of miR-17-92 components as
observed experimentally. Therefore, RNA-binding proteins may
play a role in selectively targeting and regulating miRNAs of the
cluster during processing.
Indeed, understanding the biological role of miR-17-92 clus-
ter is essential for translating bench knowledge to the bedside.
In vitro studies revealed antitumorigenic effects of targeting miR-
17-92 in cancer cell lines. Also, in vivo animal models have
shed light into the potentiality of targeting miR-17-92 compo-
nents therapeutically. The use of intravenous delivery of anti-
miR-17-92 for the treatment of allograft medulloblastoma tumor
in immune-compromised mice resulted in blockage of tumor
growth (23), indicating miR-17-92 as a feasible therapeutic tar-
get. However, some issues regarding selective anti-miR delivery
to cancer cells and its side effects in animal models still need
to be addressed by further studies in order to permit the safe
application of anti-miR-17-92 as a therapeutic adjuvant for cancer
treatment.
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